Companies Launch Marketing Of TysabriŽ For Relapsing MS
Background on TysabriŽ
TysabriŽ (natalizumab, sponsored by Biogen Idec and Elan Pharmaceuticals) is a monoclonal antibody given by infusion into a vein every four weeks. This drug was on the market for four months as a therapy for relapsing MS until it was withdrawn from the market in February 2005 due to safety concerns.
|Last updated January 28, 2008|